diabetes cat

Educational resources

Screen Shot 2019-10-22 at 11.25.04

Real-world evidence in the management of type 2 diabetes: switching from other DPP‑4 inhibitors to alogliptin (Vipidia®)

2019-10-22T10:56:00+01:00Commissioned by Takeda UK Ltd

This promotional educational webinar has been organised and funded by Takeda UK Ltd. See bottom of page for full disclaimer.

20181214 Ozempic prescribing summary card cover half

Ozempic® ▼ (semaglutide) 1.34 mg/ml once‑weekly GLP-1 RA


Commissioned by Novo Nordisk Limited

Final version_Ozempic SMC card PI update

Semaglutide 0.25 mg, 0.5 mg and 1 mg solution for injection in pre-filled pen (Ozempic®▼) SMC No. (2092)

2019-02-11T12:51:00+00:00Funded by Novo Nordisk Limited

Information intended for healthcare professionals only.

Related Guidelines in Practice articles